Chemical Safety Software is very proud to announce that another one of our clients, Moderna Inc., is currently in the spotlight in the fight against COVID- 19. Moderna (NASDAQ: MRNA) announced in May 2020 of promising early results for its Coronavirus vaccine. Moderna is one of the early front runners to develop a vaccine for COVID-19, which has killed more than 98,000 Americans, and 255,000 people worldwide. The biotech company’s vaccine produces neutralizing antibodies that bind to the virus and disable it from attacking human cells.
Moderna said its trial testing has included the vaccinations of dozens of participants and measured antibodies in eight of them.
All eight participants developed neutralizing antibodies to the virus at levels reaching or exceeding the levels seen in people who have naturally recovered from COVID-19, the company said.
If future studies go well, Moderna has said its vaccine could be available to the public as early as January 2021.